The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION Study

Introduction: Dapoxetine is a short-acting selective serotonin reuptake inhibitor for treatment of premature ejaculation (PE). Aim: To evaluate the efficacy and safety of dapoxetine 30 and 60 mg as needed in Asia-Pacific men with PE. Methods: The study was a prospective, 12-week, open-label study to...

Full description

Bibliographic Details
Main Authors: Chris McMahon, MBBS, FAChSHM, Sung Won Lee, MD, PhD, Sae Woong Kim, MD, PhD, Du Geon Moon, MD, Apichat Kongkanand, MD, Kavirach Tantiwongse, MD
Format: Article
Language:English
Published: Oxford University Press 2016-03-01
Series:Sexual Medicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2050116116000088
_version_ 1797716107248795648
author Chris McMahon, MBBS, FAChSHM
Sung Won Lee, MD, PhD
Sae Woong Kim, MD, PhD
Du Geon Moon, MD
Apichat Kongkanand, MD
Kavirach Tantiwongse, MD
author_facet Chris McMahon, MBBS, FAChSHM
Sung Won Lee, MD, PhD
Sae Woong Kim, MD, PhD
Du Geon Moon, MD
Apichat Kongkanand, MD
Kavirach Tantiwongse, MD
author_sort Chris McMahon, MBBS, FAChSHM
collection DOAJ
description Introduction: Dapoxetine is a short-acting selective serotonin reuptake inhibitor for treatment of premature ejaculation (PE). Aim: To evaluate the efficacy and safety of dapoxetine 30 and 60 mg as needed in Asia-Pacific men with PE. Methods: The study was a prospective, 12-week, open-label study to evaluate the efficacy and safety of flexible-dose dapoxetine in men with PE diagnosed by a Premature Ejaculation Diagnostic Tool score of at least 11, a self-estimated intravaginal ejaculation latency time (IELT) no longer than 2 minutes, and an International Index of Erectile Function erectile function domain score of at least 21. Main Outcome Measures: Percentage of subjects reporting their PE as at least “slightly better” using the Clinical Global Impression of Change (CGIC) question. Results: Two hundred eighteen of 285 randomized subjects completed the study. The mean subject age was 45.9 years and 57.7% were Korean. Dosages 1 (30 mg), 2 (30 → 60 mg), and 3 (30 → 60 → 30 mg) were used in 141, 124, and 13 subjects, respectively. At study end, a PE CGIC rating of at least “slightly better” was reported by 77.3%, 92.8%, and 100% of subjects for dosages 1, 2, and 3, respectively (P = .49). At study end, a CGIC rating of “slightly better” was reported by 85.2% and 85.3% of subjects with lifelong PE and acquired PE, respectively (P = .50). At study end, a CGIC rating of “slightly better” was reported by 84.1% and 86.4% of subjects with an estimated baseline IELT no longer than and at least ≤1 minute, respectively (P = .16). The incidence of a CGIC rating of at least “slightly better” was lower in subjects reporting an adverse event of moderate or severe severity and in subjects who increased to and maintained a dapoxetine dose of 60 mg and higher in subjects older than 50 years and in subjects with a baseline estimated IELT of at least 1 minute. Conclusion: In this study, flexible dosing of dapoxetine (30 and 60 mg) appeared effective in the treatment of PE.
first_indexed 2024-03-12T08:16:37Z
format Article
id doaj.art-32db001ea1d84aabbbf6a65f497eb8bb
institution Directory Open Access Journal
issn 2050-1161
language English
last_indexed 2024-03-12T08:16:37Z
publishDate 2016-03-01
publisher Oxford University Press
record_format Article
series Sexual Medicine
spelling doaj.art-32db001ea1d84aabbbf6a65f497eb8bb2023-09-02T18:45:49ZengOxford University PressSexual Medicine2050-11612016-03-0141e18e2710.1016/j.esxm.2015.12.006The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION StudyChris McMahon, MBBS, FAChSHM0Sung Won Lee, MD, PhD1Sae Woong Kim, MD, PhD2Du Geon Moon, MD3Apichat Kongkanand, MD4Kavirach Tantiwongse, MD5Australian Centre for Sexual Health, St. Leonards, NSW, AustraliaDepartment of Urology, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDepartment of Urology, Catholic University, Seoul St. Mary's Hospital, Seoul, Republic of KoreaDepartment of Urology, Korea University College of Medicine, Seoul, Republic of KoreaDepartment of Urology, Bumrungrad International Hospital, Wattana, Bangkok, ThailandDepartment of Urology, Bumrungrad International Hospital, Wattana, Bangkok, ThailandIntroduction: Dapoxetine is a short-acting selective serotonin reuptake inhibitor for treatment of premature ejaculation (PE). Aim: To evaluate the efficacy and safety of dapoxetine 30 and 60 mg as needed in Asia-Pacific men with PE. Methods: The study was a prospective, 12-week, open-label study to evaluate the efficacy and safety of flexible-dose dapoxetine in men with PE diagnosed by a Premature Ejaculation Diagnostic Tool score of at least 11, a self-estimated intravaginal ejaculation latency time (IELT) no longer than 2 minutes, and an International Index of Erectile Function erectile function domain score of at least 21. Main Outcome Measures: Percentage of subjects reporting their PE as at least “slightly better” using the Clinical Global Impression of Change (CGIC) question. Results: Two hundred eighteen of 285 randomized subjects completed the study. The mean subject age was 45.9 years and 57.7% were Korean. Dosages 1 (30 mg), 2 (30 → 60 mg), and 3 (30 → 60 → 30 mg) were used in 141, 124, and 13 subjects, respectively. At study end, a PE CGIC rating of at least “slightly better” was reported by 77.3%, 92.8%, and 100% of subjects for dosages 1, 2, and 3, respectively (P = .49). At study end, a CGIC rating of “slightly better” was reported by 85.2% and 85.3% of subjects with lifelong PE and acquired PE, respectively (P = .50). At study end, a CGIC rating of “slightly better” was reported by 84.1% and 86.4% of subjects with an estimated baseline IELT no longer than and at least ≤1 minute, respectively (P = .16). The incidence of a CGIC rating of at least “slightly better” was lower in subjects reporting an adverse event of moderate or severe severity and in subjects who increased to and maintained a dapoxetine dose of 60 mg and higher in subjects older than 50 years and in subjects with a baseline estimated IELT of at least 1 minute. Conclusion: In this study, flexible dosing of dapoxetine (30 and 60 mg) appeared effective in the treatment of PE.http://www.sciencedirect.com/science/article/pii/S2050116116000088DapoxetinePremature EjaculationPASSION Study
spellingShingle Chris McMahon, MBBS, FAChSHM
Sung Won Lee, MD, PhD
Sae Woong Kim, MD, PhD
Du Geon Moon, MD
Apichat Kongkanand, MD
Kavirach Tantiwongse, MD
The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION Study
Sexual Medicine
Dapoxetine
Premature Ejaculation
PASSION Study
title The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION Study
title_full The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION Study
title_fullStr The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION Study
title_full_unstemmed The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION Study
title_short The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION Study
title_sort asia pacific flexible dose study of dapoxetine and patient satisfaction in premature ejaculation therapy the passion study
topic Dapoxetine
Premature Ejaculation
PASSION Study
url http://www.sciencedirect.com/science/article/pii/S2050116116000088
work_keys_str_mv AT chrismcmahonmbbsfachshm theasiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT sungwonleemdphd theasiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT saewoongkimmdphd theasiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT dugeonmoonmd theasiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT apichatkongkanandmd theasiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT kavirachtantiwongsemd theasiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT chrismcmahonmbbsfachshm asiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT sungwonleemdphd asiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT saewoongkimmdphd asiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT dugeonmoonmd asiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT apichatkongkanandmd asiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy
AT kavirachtantiwongsemd asiapacificflexibledosestudyofdapoxetineandpatientsatisfactioninprematureejaculationtherapythepassionstudy